Comparison of Time to Next Treatment Between Patients With Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib Overall and in a Subgroup With High-Risk Characteristics

被引：0

作者：

Jacobs, Ryan ^{[1
]}

Levy, Moshe Y. ^{[2
]}

Yazbeck, Victor ^{[3
]}

Lafeuille, Marie-Helene ^{[4
]}

Emond, Bruno ^{[4
]}

Gogna, Priyanka ^{[4
]}

Maegawa, Rodrigo ^{[5
]}

Qureshi, Zaina P. ^{[5
]}

Ferrajoli, Alessandra ^{[6
]}

机构：

[1] Atrium Hlth Levine Canc Inst, Charlotte, NC USA

[2] Baylor Scott & White Res Inst, Dallas, TX USA

[3] VCU Hlth, Richmond, VA USA

[4] Anal Grp Inc, Montreal, PQ, Canada

[5] Janssen Sci Affairs, LLC, Horsham, PA USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

关键词：

CLL; chronic lymphocytic leukemia; ibrutinib; acalabrutinib; time to next treatment;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CLL-342

引用

页码：S351 / S351

页数：1